Idronoxil

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameIdronoxil
Drug Alias Name脱氢雌马酚Dehydroequol苯妥帝尔Haganin EVeyonda +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine kinase 2 inhibitorsSphingosine kinase 1 inhibitorsStimulator of interferon genes inhibitors +[5] 
TargetsSphingosine kinase 1Sphingosine kinase 2Stimulator of interferon genes +[5] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursProstatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNoxopharm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNoxopharm Ltd
Inactive CompaniesYale UniversityKazia Therapeutics LtdMei Pharma Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsSolid tumoursProstatic NeoplasmsFallopian Tube Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBank